Home>Video>Pharmacy Benefit Managers Weigh on Drug Retailers

Pharmacy Benefit Managers Weigh on Drug Retailers

Tue, 8 May 2012

The increasing power of PBM's like Express Scripts is putting pressure on drugstores, according to Morningstar's Matt Coffina.


Video Transcript

Jeremy Glaser: For Morningstar, I'm Jeremy Glaser. The Wall Street Journal recently named six Morningstar equity analysts Best on the Street. I'm here with Matt Coffina. He was named one of the top drug and food retail analysts. We're going to talk about some of the trends facing the sector in 2012 and his top picks.

Matt, thanks for joining me today.

Matt Coffina: Thanks for having me, Jeremy.

Glaser: So, first off, what are some of the major trends that are going to be affecting the drug retailers throughout this next year?

Coffina: So the two big issues affecting this space are really--at least in the near term--are the mergers that have happened: Express Scripts buying Medco, the two largest pharmacy benefit managers or two of the three largest getting together to form a new PBM that will be 50% larger than their next largest competitor. Also, we heard in an announcement that SXC Health Solutions plans to buy Catalyst Health Solutions, which are two smaller PBMs in the industry, but that move still speaks the general trend of consolidation.

And then on the other hand, there's the dispute between Walgreen, which is the nation's largest pharmacy chain, and Express Scripts, again where Express Scripts basically excluded Walgreen from its pharmacy network. 

Both of these trends will have a big impact on the drug supply chain and retail drugstores, in particular. Both of them you could say would be negative trends for the retail drugstores and positive for the PBMs, the companies that actually run the drug benefits.

Glaser: If you look at winners and losers there, with Walgreen losing Express Scripts, does that create an opportunity for other retailers? Or does this end up being pretty much a wash?

Coffina: No, it absolutely does [create opportunity]. Express Scripts accounted for about 12% of Walgreen's pharmaceutical sales, and Walgreen is losing about 85% of that business right away as of January. Those numbers for the most part are flowing to other pharmacy chains, and CVS Caremark has been the most visible beneficiary of that. So, patients are basically forced to leave Walgreen, and they end up going to CVS.

Glaser: With everything going on in this space seems like there are a lot of customers up for grabs. It seems a little bit fluid. What's happened with valuation levels? Are the stocks trading at attractive levels?

Coffina: We think most companies in this industry are about fairly valued. The one that stands out really is Express Scripts. It's trading for about [$18 lower than] our fair value estimate. Basically, we don't think that the market has given the company credit for the synergies it is likely to realize through the Medco acquisition and as a result, we think that investors that buy the stock at this level can capture most of those synergies.

Glaser: Do you have any other names that look attractive right now?

Coffina: Outside of the drugstore business, I do like WellPoint. I also cover the managed-care companies, and WellPoint looks particularly undervalued. It has about a 13% free cash flow yield trading for less than 9 times this year's earnings. So it's not a great growth story, but valuationwise we think the company is quite cheap.

Glaser: Well, Matt, congratulations and thanks for talking with me today.

Coffina: Thank you.

Glaser: For Morningstar, I am Jeremy Glaser.

  1. Related Videos
  2. Related Articles
  1. Insurance Companies Look East for Growth

    With the U.S. market for life insurance mature, firms are increasingly looking to Asia for growth, says Morningstar's Drew Woodbury.

  2. Can Gold Miners Catch Up to Gold?

    Morningstar's Joung Park explores why gold miners have lagged gold prices in recent years and what needs to happen for that trend to reverse.

  3. Auto Recovery Revving Up

    After a few false starts, the auto industry is finally hitting a setback-free recovery in 2012, according to Morningstar's Dave Whiston.

  4. PBMs: Health Care's Hidden Gems

    Pharmacy benefit managers aren't household names, but recent consolidation in the industry is proving out the power of scale for these firms, says Morningstar's Matt Coffina.

  5. A Rare, Wide -Moat Find in a Market With Few Values

    Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.

  6. Facebook a Future Advertising Force

    Morningstar's Rick Summer sees Facebook and Google dominating the Internet advertising market as Facebook finds better ways to monetize its massive user base.

  7. 5 Signs of Fallout in the Market

    Morningstar markets editor Jeremy Glaser studies possible impacts of the Facebook IPO controversy, struggles and turnarounds at Dell and HP, real economy weakness in the eurozone, and slower sales at Tiffany.

  8. Why Berkshire's Moat Isn't Going Away Anytime Soon

    Morningstar's Gregg Warren says Berkshire's sterling balance sheet, strong business, and unique structure will sustain the firm's competitive standing--even without Buffett.

©2017 Morningstar Advisor. All right reserved.